HAVCR2 and neoplasm: In preclinical models, tumor-derived exosomes have been shown to impair CAR T cell function by increasing inhibitory receptors such as CTLA4 and TIM-3, hindering antigen-specific CAR T cell proliferation and cytotoxicity.